<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2018-5-79-91</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-1083</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Антигипертензивные препараты в профилактике когнитивных нарушений и деменции: фокус на антагонисты кальция и диуретики</article-title><trans-title-group xml:lang="en"><trans-title>Antihypertension drugs in prevention of cognition disorder and dementia: focus on calcium channel blockers and diuretics</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0795-8225</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остроумова</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostroumova</surname><given-names>O. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Профессор, доктор медицинских наук, профессор кафедры факультетской терапии и профболезней МГМСУ им. А.И. Евдокимова, РФпрофессор кафедры клинической фармакологии и пропедевтики внутренних болезней ЦГМАУДП.</p><p>Тел.: +7 (903) 169-68-28</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">ostroumova.olga@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3091-7904</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черняева</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernyaeva</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, доцент кафедры внутренних болезней и профилактической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России; ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff><aff xml:lang="en"><institution>Evdokimov Moscow State University of Medicine and Dentistry (MSUMD); Sechenov First Moscow State University of the Ministry of Health (the Sechenov University)</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ ДПО Центральная государственная медицинская академия Управления делами Президента Российской Федерации</institution></aff><aff xml:lang="en"><institution>Central State Medical Academy of the President Office</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2018</year></pub-date><volume>17</volume><issue>5</issue><fpage>79</fpage><lpage>91</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Остроумова О.Д., Черняева М.С., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Остроумова О.Д., Черняева М.С.</copyright-holder><copyright-holder xml:lang="en">Ostroumova O.D., Chernyaeva M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/1083">https://cardiovascular.elpub.ru/jour/article/view/1083</self-uri><abstract><p>Артериальная гипертония ассоциирована с повышенным риском снижения когнитивных функций и развития сосудистой деменции и болезни Альцгеймера. В этом контексте антигипертензивная терапия может иметь профилактический эффект. Представленные в настоящем обзоре литературные данные свидетельствуют о том, что, несмотря на наличие некоторых противоречий в результатах исследований, антигипертензивные препараты, особенно дигидропиридиновые антагонисты кальция, диуретики и некоторые блокаторы ренин-ангиотензин-альдостероновой системы, обладают церебропротективными свойствами, причем не только за счет снижения артериального давления, но также и посредством дополнительных специфических нейропротективных механизмов. Это позволяет рассматривать антагонисты кальция и диуретики в качестве важного компонента лечения артериальной гипертонии, в т.ч. у пациентов пожилого и старческого возрастов, для профилактики снижения когнитивных функций и развития разных типов деменции.</p><p>Нитрендипин среди антагонистов кальция и индапамид среди диуретиков обладают наибольшей доказательной базой, свидетельствующей о наличии у них выраженных церебропротективных свойств.</p></abstract><trans-abstract xml:lang="en"><p>Arterial hypertension is associated with elevated risk of cognition decline and vascular dementia development, as the Alzheimer disease development. Therefore, antihypertension therapy might be of preventive value. The review is focused on literary data that witness on, despite controversial, evidence of cerebroprotective action of the range of antihypertension medications. Especially, dihydropyridine calcium antagonists, diuretics and some blockers of renin-angiotensin-aldosterone system. These act not only via blood pressure decrease, but due to additional specific neuroprotective mechanisms. This makes it to consider calcium antagonists and diuretics as a major component of systemic hypertension management, incl. elderly and senile patients, aiming to prevent cognition decline and dementia of various types development.</p><p>Nitrendipine, among the calcium channels antagonists, and indapamide among diuretics have acquired the broadest evidence that points on their cerebroprotective properties.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>антигипертензивная терапия</kwd><kwd>когнитивные функции</kwd><kwd>сосудистая деменция</kwd><kwd>болезнь Альцгеймера</kwd><kwd>нитренди-пин</kwd><kwd>индапамид</kwd></kwd-group><kwd-group xml:lang="en"><kwd>antihypertension therapy</kwd><kwd>cognitive functioning</kwd><kwd>vascular dementia</kwd><kwd>Alzheimer disease</kwd><kwd>nitrendipine</kwd><kwd>indapamide</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Яхно Н. Н., Захаров В. В., Локшина А. Б. и др. Деменции: руководство для врачей. М. : МЕДпресс-информ; 2011. 264 с. ISBN 978-5-98322-723-1.</mixed-citation><mixed-citation xml:lang="en">Yahno NN, Zaharov VV, Lokshina AB, et al. Dementia: guidelines for doctors. Moscow: MED press-inform; 2011. 264 p. (In Russ.) Яхно Н. Н., Захаров В. В., Локшина А. Б. и др. Деменции: руководство для врачей. М. : МЕДпресс-информ; 2011. 264 с. ISBN 978-5-98322-723-1.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Дамулин И. В. Когнитивные расстройства. Некоторые вопросы клиники, диагностики, лечения. М.; 2012. 19 с.</mixed-citation><mixed-citation xml:lang="en">Damulin IV. Cognitive disorder. Some issues of clinical picture, diagnosis, therapy. Moscow; 2012. 19 p. (In Russ.) Дамулин И. В. Когнитивные расстройства. Некоторые вопросы клиники, диагностики, лечения. М.; 2012. 19 с.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rouch L, Cestac P, Hanon O, et al. Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms. CNS Drugs. 2015;29(2):113-30. doi:10.1007/s40263-015-0230-6.</mixed-citation><mixed-citation xml:lang="en">Rouch L, Cestac P, Hanon O, et al. Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms. CNS Drugs. 2015;29(2):113-30. doi:10.1007/s40263-015-0230-6.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-7 doi:10.1016/S0140-6736(05)67889-0.</mixed-citation><mixed-citation xml:lang="en">Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-7 doi:10.1016/S0140-6736(05)67889-0.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009;72(4):368-74. doi: 101212/01.wnl.0000341271.90478.8e.</mixed-citation><mixed-citation xml:lang="en">Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009;72(4):368-74. doi: 101212/01.wnl.0000341271.90478.8e.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">б. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487-99. doi: 101016/S1474-4422(05)70141-1.</mixed-citation><mixed-citation xml:lang="en">б.	Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487-99. doi: 101016/S1474-4422(05)70141-1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Iadecola C, Yaffe K, Biller J, et al. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension. 2016;68(6):e67-94. doi:10.1161/HYP.0000000000000053.</mixed-citation><mixed-citation xml:lang="en">Iadecola C, Yaffe K, Biller J, et al. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension. 2016;68(6):e67-94. doi:10.1161/HYP.0000000000000053.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014;19(1):7-94. doi:10.1093/euroheartj/eht151.</mixed-citation><mixed-citation xml:lang="en">2013 ESH/ESC Guidelines for the management of arterial hypertension. Russ J Cardiol. 2014;19(1):7-94. (In Russ.) Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014;19(1):7-94. doi:10.1093/euroheartj/eht151.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fournier A, Oprisiu-Fournier R, Serot JM, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9(9):1413-31. doi:10.1586/ern.09.89.</mixed-citation><mixed-citation xml:lang="en">Fournier A, Oprisiu-Fournier R, Serot JM, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9(9):1413-31. doi:10.1586/ern.09.89.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shah K, Qureshi S, Johnson M, et al. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother. 2009;7(5):250-61. doi:10.1016/j.amjopharm.2009.11.001.</mixed-citation><mixed-citation xml:lang="en">Shah K, Qureshi S, Johnson M, et al. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother. 2009;7(5):250-61. doi:10.1016/j.amjopharm.2009.11.001.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tzourio C, Dufouil C, Ducimetiere P, et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of vascular aging. Neurology. 1999;53(9):1948-52.</mixed-citation><mixed-citation xml:lang="en">Tzourio C, Dufouil C, Ducimetiere P, et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of vascular aging. Neurology. 1999;53(9):1948-52.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hajjar I, Catoe H, Sixta S, et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci. 2005;60(1):67-73.</mixed-citation><mixed-citation xml:lang="en">Hajjar I, Catoe H, Sixta S, et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci. 2005;60(1):67-73.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Qiu C, von Strauss E, Fastbom J, et al. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003;60(2):223-8.</mixed-citation><mixed-citation xml:lang="en">Qiu C, von Strauss E, Fastbom J, et al. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003;60(2):223-8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686-92. doi:10.1001/archneur.63.5.noc60013.</mixed-citation><mixed-citation xml:lang="en">Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686-92.	doi:10.1001/archneur.63.5.noc60013.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Peila R, White LR, Masaki K, et al. Reducing the risk of dementia: efficacy of 39. long-term treatment of hypertension. Stroke. 2006;37(5):1165-70. doi:10.1161/01.STR.0000217653.01615.93.</mixed-citation><mixed-citation xml:lang="en">Peila R, White LR, Masaki K, et al. Reducing the risk of dementia: efficacy of 39. long-term treatment of hypertension. Stroke. 2006;37(5):1165-70. doi:10.1161/01.STR.0000217653.01615.93.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Li N-C, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of 40. dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465. doi:10.1136/bmj.b5465.</mixed-citation><mixed-citation xml:lang="en">Li N-C, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of 40. dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465. doi:10.1136/bmj.b5465.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson ML, Parikh N, Kunik ME, et al. Antihypertensive drug use and the risk of 41. dementia in patients with diabetes mellitus. Alzheimers Dement. 2012;8(5):437-44. doi:10.1016/j.jalz.2011.05.2414.</mixed-citation><mixed-citation xml:lang="en">Johnson ML, Parikh N, Kunik ME, et al. Antihypertensive drug use and the risk of 41. dementia in patients with diabetes mellitus. Alzheimers Dement. 2012;8(5):437-44. doi:10.1016/j.jalz.2011.05.2414.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yasar S, Xia J, Yao W, et al. Antihypertensive drugs decrease risk of Alzheimer 42. disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896-903. doi:10.1212/WNL.0b013e3182a35228.</mixed-citation><mixed-citation xml:lang="en">Yasar S, Xia J, Yao W, et al. Antihypertensive drugs decrease risk of Alzheimer 42. disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896-903. doi:10.1212/WNL.0b013e3182a35228.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Haag MDM, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use 43. and risk of dementia: a prospective cohort study. Neurology. 2009;72(20):1727-34. doi:10.1212/01.wnl.0000345062.86148.3f.</mixed-citation><mixed-citation xml:lang="en">Haag MDM, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use 43. and risk of dementia: a prospective cohort study. Neurology. 2009;72(20):1727-34. doi:10.1212/01.wnl.0000345062.86148.3f.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">In't Veld BA, Ruitenberg A, Hofman A, et al. Antihypertensive drugs and incidence of 44. dementia: the Rotterdam Study. Neurobiol Aging. 2001;22(3):407-12.</mixed-citation><mixed-citation xml:lang="en">In't Veld BA, Ruitenberg A, Hofman A, et al. Antihypertensive drugs and incidence of 44. dementia: the Rotterdam Study. Neurobiol Aging. 2001;22(3):407-12.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Chiu WC, Ho WC, Lin MH, et al. Angiotension receptor blockers reduce the risk of dementia. J Hypertens. 2014;32(4):938-47 doi:10.1097/HJH.0000000000000086.</mixed-citation><mixed-citation xml:lang="en">Chiu WC, Ho WC, Lin MH, et al. Angiotension receptor blockers reduce the risk of dementia. J Hypertens. 2014;32(4):938-47 doi:10.1097/HJH.0000000000000086.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Morris MC, Scherr PA, Hebert LE, et al. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol. 2001;58(10):1640-6.</mixed-citation><mixed-citation xml:lang="en">Morris MC, Scherr PA, Hebert LE, et al. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol. 2001;58(10):1640-6.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156(5):445-53.</mixed-citation><mixed-citation xml:lang="en">Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156(5):445-53.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Yasar S, Corrada M, Brookmeyer R, et al. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 2005;26(2): 157-63. doi:10.1016/j.neurobiolaging.2004.03.009.</mixed-citation><mixed-citation xml:lang="en">Yasar S, Corrada M, Brookmeyer R, et al. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 2005;26(2): 157-63. doi:10.1016/j.neurobiolaging.2004.03.009.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomized trial. BMJ. 2002;324(7339):699-702</mixed-citation><mixed-citation xml:lang="en">Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomized trial. BMJ. 2002;324(7339):699-702</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme 49. inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53. doi:10.1056/NEJM200001203420301.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme 49. inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53. doi:10.1056/NEJM200001203420301.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069-75. doi:10.1001/archinte.163.9.1069.</mixed-citation><mixed-citation xml:lang="en">Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069-75. doi:10.1001/archinte.163.9.1069.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304(6824):405-12.</mixed-citation><mixed-citation xml:lang="en">Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304(6824):405-12.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients 52. affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996;312(7034):801-5.</mixed-citation><mixed-citation xml:lang="en">Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients 52. affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996;312(7034):801-5.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J 53. Hypertens. 2003;21(5):875-86. doi:10.1097/01.hjh.0000059028.82022.89.</mixed-citation><mixed-citation xml:lang="en">Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind	intervention trial. J	53. Hypertens. 2003;21(5):875-86. doi:10.1097/01.hjh.0000059028.82022.89.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.</mixed-citation><mixed-citation xml:lang="en">Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-9. doi:10.1016/S1474-4422(08)70143-1.</mixed-citation><mixed-citation xml:lang="en">Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-9. doi:10.1016/S1474-4422(08)70143-1.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875-84. doi:10.1016/S1474-4422(08)70198-4.</mixed-citation><mixed-citation xml:lang="en">Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875-84. doi:10.1016/S1474-4422(08)70198-4.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10(1):43-53. doi:10.1016/S1474-4422(10)70250-7.</mixed-citation><mixed-citation xml:lang="en">Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10(1):43-53. doi:10.1016/S1474-4422(10)70250-7.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.</mixed-citation><mixed-citation xml:lang="en">Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154(19):2154-60.</mixed-citation><mixed-citation xml:lang="en">Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154(19):2154-60.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-64.</mixed-citation><mixed-citation xml:lang="en">Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-64.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Forette F, Seux M-L, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046-52.</mixed-citation><mixed-citation xml:lang="en">Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomized doubleblind placebo-controlled Systolic Hypertension In Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347-51.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073-82. doi:10.1097/HJH.0b013e3283603f53.</mixed-citation><mixed-citation xml:lang="en">Forette F, Seux M-L, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046-52.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Yasar S, Schuchman M, Peters J, et al. Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. Curr Hypertens Rep. 2016;18(8):67. doi:10.1007/s11906-016-0674-1.</mixed-citation><mixed-citation xml:lang="en">Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073-82. doi:10.1097/HJH.0b013e3283603f53.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Peters R, Collerton J, Granic A, et al. Antihypertensive drug use and risk of cognitive decline in the very old: an observational study — the Newcastle 85+ Study. J Hypertens. 2015;33(10):2156-64. doi:10.1097/HJH.0000000000000653.</mixed-citation><mixed-citation xml:lang="en">Yasar S, Schuchman M, Peters J, et al. Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. Curr Hypertens Rep. 2016;18(8):67. doi:10.1007/s11906-016-0674-1.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Chuang YF, Breitner JCS, Chiu YL, et al. Use of diuretics is associated with reduced risk of Alzheimer's disease. The Cache County Study. Neurobiol Aging. 2014;35(11):2429-35. doi:10.1016/j.neurobiolaging.2014.05.002.</mixed-citation><mixed-citation xml:lang="en">Peters R, Collerton J, Granic A, et al. Antihypertensive drug use and risk of cognitive decline in the very old: an observational study — the Newcastle 85+ Study. J Hypertens. 2015;33(10):2156-64. doi:10.1097/HJH.0000000000000653.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Wagner G, Icks A, Abholz HH, et al. Antihypertensive treatment and risk of dementia: a retrospective database study. Int J Clin Pharmacol Ther. 2012;50(3):195-201. doi:10.5414/CP201284.</mixed-citation><mixed-citation xml:lang="en">Chuang YF, Breitner JCS, Chiu YL, et al. Use of diuretics is associated with reduced risk of Alzheimer's disease. The Cache County Study. Neurobiol Aging. 2014;35(11):2429-35. doi:10.1016/j.neurobiolaging.2014.05.002.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Gelber R, Ross G, Petrovitch H, et al. Antihypertensive medication use and risk of cognitive impairment. The Honolulu-Asia Aging Study Neurology. 2013;81:888-95. doi:10.1212/WNL.0b013e3182a351d4.</mixed-citation><mixed-citation xml:lang="en">Wagner G, Icks A, Abholz HH, et al. Antihypertensive treatment and risk of dementia: a retrospective database study. Int J Clin Pharmacol Ther. 2012;50(3):195-201. doi:10.5414/CP201284.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Tully PJ, Hanon O, Cosh S, et al. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, meta-analysis and meta-regression of prospective studies. J Hypertens. 2016;34(6):1027-35. doi:10.1097/HJH.0000000000000868.</mixed-citation><mixed-citation xml:lang="en">Gelber R, Ross G, Petrovitch H, et al. Antihypertensive medication use and risk of cognitive impairment. The Honolulu-Asia Aging Study Neurology. 2013;81:888-95. doi:10.1212/WNL.0b013e3182a351d4.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Davies N, Kehoe P, Shlomo YB, et al. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis. 2014;26(4):699-708. doi:10.3233/JAD-2011-110347.</mixed-citation><mixed-citation xml:lang="en">Tully PJ, Hanon O, Cosh S, et al. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, meta-analysis and meta-regression of prospective studies. J Hypertens. 2016;34(6):1027-35. doi:10.1097/HJH.0000000000000868.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Solfrizzi V, Scafato E, Frisardi V, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age (Dordr). 2013;35(2):441-53. doi:10.1007/s11357-011-9360-z.</mixed-citation><mixed-citation xml:lang="en">Davies N, Kehoe P, Shlomo YB, et al. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis. 2014;26(4):699-708. doi:10.3233/JAD-2011-110347.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu CY, Huang CC, Chan WL, et al. Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population—a nationwide cohort study. Circ J. 2013;77(2):405-10. doi:10.1253/circj.CJ-12-0658.</mixed-citation><mixed-citation xml:lang="en">Solfrizzi V, Scafato E, Frisardi V, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age (Dordr). 2013;35(2):441-53. doi:10.1007/s11357-011-9360-z.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Wu CL, Wen SH. A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. Medicine (Baltimore). 2016;95(32):e4593. doi:10.1097/MD.0000000000004593.</mixed-citation><mixed-citation xml:lang="en">Hsu CY, Huang CC, Chan WL, et al. Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population—a nationwide cohort study. Circ J. 2013;77(2):405-10. doi:10.1253/circj.CJ-12-0658.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Hussain S, Singh A, Rahman SO, et al. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies. Neurosci Lett. 2018;671:120-7. doi:10.1016/j.neulet.2018.02.027.</mixed-citation><mixed-citation xml:lang="en">Wu CL, Wen SH. A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. Medicine (Baltimore). 2016;95(32):e4593.	doi:10.1097/MD.0000000000004593.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015;6(4):160-9. doi:10.1177/2040622315582353.</mixed-citation><mixed-citation xml:lang="en">Hussain S, Singh A, Rahman SO, et al. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies. Neurosci Lett. 2018;671:120-7. doi:10.1016/j.neulet.2018.02.027.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590):829-40. doi:10.1016/S0140-6736(07)61303-8.</mixed-citation><mixed-citation xml:lang="en">Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015;6(4):160-9. doi:10.1177/2040622315582353.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Rastas S, Pirttila T, Mattila K, et al. Vascular risk factors and dementia in the general population aged &gt;85 years. Prospective population-based study. Neurobiol Aging. 2010;31(1):1-7 doi:10.1016/j.neurobiolaging.2008.02.020.</mixed-citation><mixed-citation xml:lang="en">Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590):829-40. doi:10.1016/S0140-6736(07)61303-8.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Guo Z, Fratiglioni L, Zhu L, et al. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol. 1999;56(8):991-6.</mixed-citation><mixed-citation xml:lang="en">Rastas S, Pirttila T, Mattila K, et al. Vascular risk factors and dementia in the general population aged &gt;85 years. Prospective population-based study. Neurobiol Aging. 2010;31(1):1-7 doi:10.1016/j.neurobiolaging.2008.02.020.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Ohrui T, Matsui T, Yamaya M, et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc. 2004;52(4):649-50. doi:10.1111/j.1532-5415.2004.52178_7.x.</mixed-citation><mixed-citation xml:lang="en">Guo Z, Fratiglioni L, Zhu L, et al. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol. 1999;56(8):991-6.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiol. 2003;22(6):316-25. doi:10.1159/000072920.</mixed-citation><mixed-citation xml:lang="en">Ohrui T, Matsui T, Yamaya M, et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc. 2004;52(4):649-50. doi:10.1111/j.1532-5415.2004.52178_7.x.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Corrada MM, Brookmeyer R, Paganini-Hill A, et al. Dementia incidence continues to increase with age in the oldest old the 90^ study. Ann Neurol. 2010 ;67(1):114-21. doi:10.1002/ana.21915.</mixed-citation><mixed-citation xml:lang="en">Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiol. 2003;22(6):316-25. doi:10.1159/000072920.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Hainsworth AH, Markus HS. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab. 2008;28(12):1877-91. doi:10.1038/jcbfm.2008.91.</mixed-citation><mixed-citation xml:lang="en">Corrada MM, Brookmeyer R, Paganini-Hill A, et al. Dementia incidence continues to increase with age in the oldest old the 90p study. Ann Neurol. 2010 ;67(1):114-21. doi:10.1002/ana.21915.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke. 1996;27(12):2262-70.</mixed-citation><mixed-citation xml:lang="en">Hainsworth AH, Markus HS. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab. 2008;28(12):1877-91. doi:10.1038/jcbfm.2008.91.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Suter OC, Sunthorn T, Kraftsik R, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. 2002 ;33(8):1986-92.</mixed-citation><mixed-citation xml:lang="en">Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke. 1996;27(12):2262-70.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol. 1997;244(3):135-42.</mixed-citation><mixed-citation xml:lang="en">Suter OC, Sunthorn T, Kraftsik R, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. 2002 ;33(8):1986-92.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Hardy JA, Mann DM, Wester P, et al. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging. 1986;7(6):489-502.</mixed-citation><mixed-citation xml:lang="en">Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol. 1997;244(3):135-42.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X, Zhou K, Wang R, et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem. 2007;282(15):10873-80. doi:10.1074/jbc.M608856200.</mixed-citation><mixed-citation xml:lang="en">Hardy JA, Mann DM, Wester P, et al. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging. 1986;7(6):489-502.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke. 2009;40(3 Suppl):S40-4. doi:10.1161/STROKEAHA.108.533638.</mixed-citation><mixed-citation xml:lang="en">Zhang X, Zhou K, Wang R, et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem. 2007;282(15):10873-80. doi:10.1074/jbc.M608856200.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103.793 subjects. Am J Hypertens. 2004;17(9):817-22. doi:10.1016/j.amjhyper.2004.06.002.</mixed-citation><mixed-citation xml:lang="en">Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke. 2009;40(3 Suppl):S40-4. doi:10.1161/STROKEAHA.108.533638.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;3:CD000147. doi:10.1002/14651858.CD000147.</mixed-citation><mixed-citation xml:lang="en">Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103.793 subjects. Am J Hypertens. 2004;17(9):817-22. doi:10.1016/j.amjhyper.2004.06.002.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Berridge MJ. Calcium signalling and Alzheimer’s disease. Neurochem Res. 2011;36(7):1149-56. doi:10.1007/s11064-010-0371-4.</mixed-citation><mixed-citation xml:lang="en">Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;3:CD000147. doi:10.1002/14651858.CD000147.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Thibault O, Gant JC, Landfield PW. Expansion of the calcium hypothesis of brain aging and Alzheimer’s disease: minding the store. Aging Cell. 2007;6(3):307-17. doi:10.1111/j.1474-9726.2007.00295.x.</mixed-citation><mixed-citation xml:lang="en">Berridge MJ. Calcium signalling and Alzheimer’s disease. Neurochem Res. 2011;36(7):1149-56. doi:10.1007/s11064-010-0371-4.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Thibault O, Landfield PW. Increase in single L-type calcium channels in hippocampal neurons during aging. Science. 1996;272(5264):1017-20.</mixed-citation><mixed-citation xml:lang="en">Thibault O, Gant JC, Landfield PW. Expansion of the calcium hypothesis of brain aging and Alzheimer’s disease: minding the store. Aging Cell. 2007;6(3):307-17. doi:10.1111/j.1474-9726.2007.00295.x.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Pierrot N, Ghisdal P, Caumont AS, et al. Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J Neurochem. 2004;88(5):1140-50.</mixed-citation><mixed-citation xml:lang="en">Thibault O, Landfield PW. Increase in single L-type calcium channels in hippocampal neurons during aging. Science. 1996;272(5264):1017-20.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Querfurth HW, Selkoe DJ. Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry (Mosc). 1994;33(15):4550-61.</mixed-citation><mixed-citation xml:lang="en">Pierrot N, Ghisdal P, Caumont AS, et al. Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J Neurochem. 2004;88(5):1140-50.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Mattson MP. Antigenic changes similar to those seen in neurofibrillary tangles are elicited by glutamate and Ca2+ influx in cultured hippocampal neurons. Neuron. 1990;4(1):105-17.</mixed-citation><mixed-citation xml:lang="en">Querfurth HW, Selkoe DJ. Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry (Mosc). 1994;33(15):4550-61.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Nixon RA. The calpains in aging and aging-related diseases. Ageing Res Rev. 2003;2(4):407-18.</mixed-citation><mixed-citation xml:lang="en">Mattson MP. Antigenic changes similar to those seen in neurofibrillary tangles are elicited by glutamate and Ca2+ influx in cultured hippocampal neurons. Neuron. 1990;4(1):105-17.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Green KN, LaFerla FM. Linking calcium to Abeta and Alzheimer’s disease. Neuron. 2008;59(2):190-4. doi:10.1016/j.neuron.2008.07.013.</mixed-citation><mixed-citation xml:lang="en">Nixon RA. The calpains in aging and aging-related diseases. Ageing Res Rev. 2003;2(4):407-18.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Kuchibhotla KV, Goldman ST, Lattarulo CR, et al. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59(2):214-25. doi:10.1016/j.neuron.2008.06.008.</mixed-citation><mixed-citation xml:lang="en">Green KN, LaFerla FM. Linking calcium to Abeta and Alzheimer’s disease. Neuron. 2008;59(2):190-4. doi:10.1016/j.neuron.2008.07.013.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Yu JT, Chang RCC, Tan L. Calcium dysregulation in Alzheimer’s disease: from mechanisms to therapeutic opportunities. Prog Neurobiol. 2009;89(3):240-55. doi:10.1016/j.pneurobio.2009.07.009.</mixed-citation><mixed-citation xml:lang="en">Kuchibhotla KV, Goldman ST, Lattarulo CR, et al. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59(2):214-25. doi:10.1016/j.neuron.2008.06.008.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997;77(4):1081-132. doi:10.1152/physrev.1997.77.4.1081.</mixed-citation><mixed-citation xml:lang="en">Yu JT, Chang RCC, Tan L. Calcium dysregulation in Alzheimer’s disease: from mechanisms to therapeutic opportunities. Prog Neurobiol. 2009;89(3):240-55. doi:10.1016/j.pneurobio.2009.07.009.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Furukawa K, Wang Y, Yao PJ, et al. Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J Neurochem. 2003;87(2):427-36.</mixed-citation><mixed-citation xml:lang="en">Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997;77(4):1081-132. doi:10.1152/physrev.1997.77.4.1081.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Trompet S, Westendorp RGJ, Kamper AM, et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging.</mixed-citation><mixed-citation xml:lang="en">Furukawa K, Wang Y, Yao PJ, et al. Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J Neurochem. 2003;87(2):427-36.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">;29(2):306-8. doi:10.1016/j.neurobiolaging.2006.10.006.</mixed-citation><mixed-citation xml:lang="en">Trompet S, Westendorp RGJ, Kamper AM, et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging. 2008;29(2):306-8. doi:10.1016/j.neurobiolaging.2006.10.006.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Lu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016;75(3):547-51. doi:10.1136/annrheumdis-2014-206917.</mixed-citation><mixed-citation xml:lang="en">Lu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016;75(3):547-51. doi:10.1136/annrheumdis-2014-206917.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Euser SM, Hofman A, Westendorp RG, et al. Serum uric acid and cognitive function and dementia. Brain. 2009;132(Pt 2):377-82. doi:10.1093/brain/awn316.</mixed-citation><mixed-citation xml:lang="en">Euser SM, Hofman A, Westendorp RG, et al. Serum uric acid and cognitive function and dementia. Brain. 2009;132(Pt 2):377-82. doi:10.1093/brain/awn316.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Al-khateeb E, Althaher A, Al-khateeb M, et al. Relation between uric acid and Alzheimer’s disease in elderly Jordanians. J Alzheimers Dis. 2015;44(3):859-65. doi:10.3233/JAD-142037.</mixed-citation><mixed-citation xml:lang="en">Al-khateeb E, Althaher A, Al-khateeb M, et al. Relation between uric acid and Alzheimer’s disease in elderly Jordanians. J Alzheimers Dis. 2015;44(3):859-65. doi:10.3233/JAD-142037.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Reyes AJ. Heart failure, dementia, and diuretics: is uric acid involved? Arch Intern Med. 2006;166(20):2286. doi:10.1001/archinte.166.20.2286.</mixed-citation><mixed-citation xml:lang="en">Reyes AJ. Heart failure, dementia, and diuretics: is uric acid involved? Arch Intern Med. 2006;166(20):2286. doi:10.1001/archinte.166.20.2286.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Hernandorena I, Duron E, Vidal JS, et al. Treatment options and considerations for hypertensive patients to prevent dementia. Exp Opin Pharmacother. 2017;18(10):989-1000. doi:10.1080/14656566.2017.1333599</mixed-citation><mixed-citation xml:lang="en">Hernandorena I, Duron E, Vidal JS, et al. Treatment options and considerations for hypertensive patients to prevent dementia. Exp Opin Pharmacother. 2017;18(10):989-1000. doi:10.1080/14656566.2017.1333599</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Syrov AV, Sturov NV. Patient of senile age with arterial hypertension in outpatient treatment. Clinical Gerontology. 2018;3-4:28-34. (In Russ.) doi: 10.26347/1607-2499201803-04028-034.</mixed-citation><mixed-citation xml:lang="en">Syrov AV, Sturov NV. Patient of senile age with arterial hypertension in outpatient treatment. Clinical Gerontology. 2018;3-4:28-34. (In Russ.) doi: 10.26347/1607-2499201803-04028-034.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo for older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16(12Pt 1):1823-9.</mixed-citation><mixed-citation xml:lang="en">Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo for older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16(12Pt 1):1823-9.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачева О.Н., Рунихина Н. К., Котовская Ю. В. и др. Лечение артериальной гипертонии у пациентов 80 лети старше и пациентов со старческой астенией. Кардиоваскулярная терапия и профилактика. 2017;16(1):8-21. doi:10.15829/1728-8800-2017-1-8-21.</mixed-citation><mixed-citation xml:lang="en">Tkacheva ON, Runikhina NK, Kotovskaya YuV, et al. Treatment of arterial hypertension in patients at theage of 80 years or older and patients with senile asthenia. Cardiovascular Therapy and Prevention. 2017;16(1):8-21 (In Russ.) doi:10.15829/1728-8800-2017-1-8-21.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Bachmeier C, Beaulieu-Abdelahad D, Mullan M, et al. Selective dihydropyiridine compounds facilitate the clearance of p-amyloid across the blood-brain barrier. Eur J Pharmacol. 2011;659(2-3):124-9. doi:10.1016/j.ejphar.2011.03.048.</mixed-citation><mixed-citation xml:lang="en">Bachmeier C, Beaulieu-Abdelahad D, Mullan M, et al. Selective dihydropyiridine compounds facilitate the clearance of p-amyloid across the blood-brain barrier. Eur J Pharmacol. 2011;659(2-3):124-9. doi:10.1016/j.ejphar.2011.03.048.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Paris D, Bachmeier C, Patel N, et al. Selective antihypertensive dihydropyridines lower Ap accumulation by targeting both the production and the clearance of Ap across the blood-brain barrier. Mol Med. 2011; 17(3-4): 149-62. doi:10.2119/molmed.2010.00180.</mixed-citation><mixed-citation xml:lang="en">Paris D, Bachmeier C, Patel N, et al. Selective antihypertensive dihydropyridines lower Ap accumulation by targeting both the production and the clearance of Ap across the blood-brain barrier. Mol Med. 2011; 17(3-4): 149-62. doi:10.2119/molmed.2010.00180.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Преображенский Д. В., Сидоренко Б. А., Шатунова И. М. и др. Тиазидные и тиазидоподобные диуретики как краеугольный камень современной антигипертензивной терапии. Российский кардиологический журнал. 2004;9(4):5-13.</mixed-citation><mixed-citation xml:lang="en">Preobrazhensky DV, Sidorenko BA, Shatunova IM, et al. Thiazide and thiazidelike diuretics as a principal choice of modern antihypertension treatment. Russ J Cardiol. 2004;9(4):5-13. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Карпов Р.С., Мордовин В. Ф. Хронические формы цереброваскулярной патологии у больных артериальной гипертонией: частота выявления, динамика развития, особенности терапии. Болезни сердца и сосудов. 2006;1(3):17-21.</mixed-citation><mixed-citation xml:lang="en">Karpov RS, Mordovin VF. Chronic forms of cerebrovascular pathology in patients with arterial hypertension: detection frequency, dynamics of development, features of therapy. Diseases of the heart and blood vessels. 2006; 1 (3): 17-21. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Lu M, Ma L, Wang X, et al. Indapamide suppresses amyloid-p production in cellular models of Alzheimer's disease through regulating BACE1 activity. Int J Clin Exp Med. 2017;10(4):5922-30.</mixed-citation><mixed-citation xml:lang="en">Lu M, Ma L, Wang X, et al. Indapamide suppresses amyloid-p production in cellular models of Alzheimer's disease through regulating BACE1 activity. Int J Clin Exp Med. 2017;10(4):5922-30.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Chillon JM, Baumbach GL. Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats. Hypertension. 2004;43(5):1092-7. doi:10.1161/01.HYP.0000122874.21730.81.</mixed-citation><mixed-citation xml:lang="en">Chillon JM, Baumbach GL. Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats. Hypertension. 2004;43(5):1092-7. doi:10.1161/01.HYP.0000122874.21730.81.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Nishioku T, Takata F, Yamauchi A, et al. Protective Action of Indapamide, a ThiazideLike Diuretic, on Ischemia-Induced Injury and Barrier Dysfunction in Mouse Brain Microvascular Endothelial Cells. J Pharmacol Sci. 2007;103(3):323-7 doi:10.1254/jphs.SC0060222.</mixed-citation><mixed-citation xml:lang="en">Nishioku T, Takata F, Yamauchi A, et al. Protective Action of Indapamide, a ThiazideLike Diuretic, on Ischemia-Induced Injury and Barrier Dysfunction in Mouse Brain Microvascular Endothelial Cells. J Pharmacol Sci. 2007;103(3):323-7 doi:10.1254/jphs.SC0060222.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С. Ю., Кутишенко Н.П., Деев А. Д. и др. Изучение эффективности и переносимости препарата Индап в сравнении с препаратами Арифон и Арифон Ретард у больных мягкой и умеренной артериальной гипертонией, назначаемых как в виде монотерапии, так и в комбинации с ингибиторами АПФ. Многоцентровое, открытое, рандомизированное перекрестное исследование. Российский кардиологический журнал. 2006;11(2):73-7</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Kutishenko NP, Deev AD, et al. Indap effectiveness and tolerability, in comparison to Arifon and Arifon retard, as monotherapy or in combination with ACE inhibitors, among patients with mild to moderate arterial hypertension. Multicenter, open, randomized, cross-over study. Russ J Cardiol. 2006;11(2):73-7. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
